What are the most promising avenues for future B cell research?

What the effector cells do is, they turn into antibody-- they turn into these effector B cells-- or sometimes they're called plasma cells. They're going to turn ... CD20 is a B cell-specific membrane protein and represents an attractive target for therapeutic antibodies. Despite widespread usage of anti-CD20 antibodies ... Sep 7, 2017 ... The US Food and Drug Administration granted regular approval to tisagenlecleucel (KYMRIAH, Novartis Pharmaceuticals Corp.) for the treatment of patients up to ... B-cell acute lymphoblastic leukemia, or B-ALL, is a bone marrow and blood cancer. B-ALL occurs at any age but more commonly in children. Aug 19, 2024 ... This trial represents the largest randomized study of radiotherapy in PMBCL to date. Despite encountering challenges due to unexpectedly good ... Thus, CD40L/CD40 and MHC class II/T cell receptor (TCR) interactions are essential for peripheral B cell tolerance. The decreased numbers of CD4+ regulatory T ( ... Dec 18, 2020 ... B cells can directly present tumor-associated antigens to T cells or produce antibodies that increase antigen presentation to T cells or kill tumor cells. B-cell lymphoproliferative disorders are conditions in the blood involving uncontrolled growth of white blood cells, also called lymphocytes. These conditions ... Sep 1, 2008 ... A simple definition of B lymphocytes is a population of cells that express clonally diverse cell surface immunoglobulin (Ig) receptors ... Oct 11, 2016 ... ... B cells during pathogenic secondary DENV infections is needed. This ... B cells yield plasmablasts and plasma cells (Seifert et al., 2015.